{"from": 0, "facets": null, "took": 4, "therapeutic_areas": [], "total": 27, "data": [{"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/26160761"}]}, "target": {"id": "ENSG00000112033", "gene_info": {"symbol": "PPARD", "name": "peroxisome proliferator activated receptor delta", "geneid": "ENSG00000112033"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's Disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/26160761", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/Q03181"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/26160761", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/26160761", "mined_sentences": [{"text": "PPAR\u03b2/\u03b4 Agonist Provides Neuroprotection by Suppression of IRE1\u03b1-Caspase-12-Mediated Endoplasmic Reticulum Stress Pathway in the Rotenone Rat Model of Parkinson's Disease.", "section": "title", "t_start": 0, "d_end": 169, "d_start": 151, "t_end": 4}, {"text": "Two recent studies demonstrated that peroxisome proliferator-activated receptor \u03b2/\u03b4 (PPAR\u03b2/\u03b4) agonists exerted neuroprotective effects in mouse model of Parkinson's disease (PD).", "section": "abstract", "t_start": 85, "d_end": 171, "d_start": 153, "t_end": 89}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 17.8}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2016-08-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.17800000000000002}, "type": "literature", "id": "85f5a5fdf6a18a1d94dcf12c340a3c97"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/25279756"}]}, "target": {"id": "ENSG00000112096", "gene_info": {"symbol": "SOD2", "name": "superoxide dismutase 2, mitochondrial", "geneid": "ENSG00000112096"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/25279756", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P04179"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/25279756", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/25279756", "mined_sentences": [{"text": "Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.", "section": "title", "t_start": 28, "d_end": 85, "d_start": 67, "t_end": 31}, {"text": "Quantitative polymerase chain reaction assays revealed that a highly ranked gene, superoxide dismutase 2 (SOD2), is upregulated in PD patients compared to healthy controls in 192 whole blood samples from two independent clinical trials, the Harvard Biomarker Study (HBS) and the Diagnostic and Prognostic Biomarkers in Parkinson's disease (PROBE).", "section": "abstract", "t_start": 106, "d_end": 337, "d_start": 319, "t_end": 109}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 17.2}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2014-01-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.172}, "type": "literature", "id": "72210b57a7be88e3af5dec5edd9adda3"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/10739641"}]}, "target": {"id": "ENSG00000182667", "gene_info": {"symbol": "NTM", "name": "neurotrimin", "geneid": "ENSG00000182667"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/10739641", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/Q9P121"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/10739641", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/10739641", "mined_sentences": [{"text": "Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease.", "section": "title", "t_start": 42, "d_end": 99, "d_start": 81, "t_end": 44}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 16.6}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2000-04-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.166}, "type": "literature", "id": "62321114d7b58cd8a91adfe8a8f47aee"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/23500098"}]}, "target": {"id": "ENSG00000112033", "gene_info": {"symbol": "PPARD", "name": "peroxisome proliferator activated receptor delta", "geneid": "ENSG00000112033"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/23500098", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/Q03181"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/23500098", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/23500098", "mined_sentences": [{"text": "A peroxisome proliferator-activated receptor-\u03b4 agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.", "section": "title", "t_start": 2, "d_end": 159, "d_start": 141, "t_end": 45}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 15.4}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2013-06-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.154}, "type": "literature", "id": "96fcbd0baf675ff16f232215f43e39b9"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/22723845"}]}, "target": {"id": "ENSG00000112096", "gene_info": {"symbol": "SOD2", "name": "superoxide dismutase 2, mitochondrial", "geneid": "ENSG00000112096"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/22723845", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P04179"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/22723845", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/22723845", "mined_sentences": [{"text": "Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease.", "section": "title", "t_start": 6, "d_end": 146, "d_start": 128, "t_end": 9}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 15.0}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2012-01-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.15}, "type": "literature", "id": "c2a461767431a25f943729fc64708e00"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/24635117"}]}, "target": {"id": "ENSG00000112033", "gene_info": {"symbol": "PPARD", "name": "peroxisome proliferator activated receptor delta", "geneid": "ENSG00000112033"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/24635117", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/Q03181"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/24635117", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/24635117", "mined_sentences": [{"text": "A PPAR-\u03b2/\u03b4 agonist is neuroprotective and decreases cognitive impairment in a rodent model of Parkinson's disease.", "section": "title", "t_start": 2, "d_end": 112, "d_start": 94, "t_end": 7}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 14.6}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2014-05-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.146}, "type": "literature", "id": "46a7fb3d59782714538d1c3029848ea2"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/25530507"}]}, "target": {"id": "ENSG00000112033", "gene_info": {"symbol": "PPARD", "name": "peroxisome proliferator activated receptor delta", "geneid": "ENSG00000112033"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/25530507", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/Q03181"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/25530507", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/25530507", "mined_sentences": [{"text": "PPAR\u03b2/\u03b4 and \u03b3 in a rat model of Parkinson's disease: possible involvement in PD symptoms.", "section": "title", "t_start": 0, "d_end": 50, "d_start": 32, "t_end": 4}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 14.4}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2015-05-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.14400000000000002}, "type": "literature", "id": "1ba5eb4ce4e9341d03a7fb165d3e2467"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/24860980"}]}, "target": {"id": "ENSG00000179218", "gene_info": {"symbol": "CALR", "name": "calreticulin", "geneid": "ENSG00000179218"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/24860980", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P27797"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/24860980", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/24860980", "mined_sentences": [{"text": "Reductions of the components of the calreticulin/calnexin quality-control system by proteasome inhibitors and their relevance in a rodent model of Parkinson's disease.", "section": "title", "t_start": 36, "d_end": 165, "d_start": 147, "t_end": 47}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 14.2}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2014-10-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.142}, "type": "literature", "id": "e83d386201722fad69c51801029e1cb1"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/11692079"}]}, "target": {"id": "ENSG00000143819", "gene_info": {"symbol": "EPHX1", "name": "epoxide hydrolase 1", "geneid": "ENSG00000143819"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/11692079", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P07099"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/11692079", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/11692079", "mined_sentences": [{"text": "In this investigation, we examined the potential association between the risk of Parkinson's disease and genetic variation within the EPHX1 and EPHX2 genes.", "section": "abstract", "t_start": 134, "d_end": 99, "d_start": 81, "t_end": 138}, {"text": "EPHX1 and EPHX2 genotype data were obtained from 133 idiopathic Parkinson's disease patients and 212 control subjects matched on age, gender and ethnicity.", "section": "abstract", "t_start": 0, "d_end": 82, "d_start": 53, "t_end": 4}, {"text": "Therefore, common polymorphisms within EPHX1 and EPHX2 do not appear to be important risk factors for Parkinson's disease.", "section": "abstract", "t_start": 39, "d_end": 120, "d_start": 102, "t_end": 43}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 14.0}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2001-11-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.14}, "type": "literature", "id": "a094cdd4c5f5a9ce7b32e7c5d8a8c41c"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/22926168"}]}, "target": {"id": "ENSG00000187323", "gene_info": {"symbol": "DCC", "name": "DCC netrin 1 receptor", "geneid": "ENSG00000187323"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/22926168", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P43146"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/22926168", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/22926168", "mined_sentences": [{"text": "Recent studies suggest a variety of factors characterize substantia nigra neurons vulnerable to Parkinson's disease, including the transcription factors pituitary homeobox 3 (Pitx3) and orthodenticle homeobox 2 (Otx2) and the trophic factor receptor deleted in colorectal cancer (DCC), but there is limited information on their expression and localization in adult humans.", "section": "abstract", "t_start": 280, "d_end": 114, "d_start": 96, "t_end": 282}, {"text": "Our data show that, at the age when Parkinson's disease typically occurs, there are no significant differences in the expression of transcription factors in brainstem dopamine neurons, but those most vulnerable to Parkinson's disease rely more on the trophic factor receptor DCC than other brainstem dopamine neurons.", "section": "abstract", "t_start": 275, "d_end": 54, "d_start": 36, "t_end": 277}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 11.0}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2013-03-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.11}, "type": "literature", "id": "78e070c97b4383df8621d5cd9bae0241"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/15730872"}]}, "target": {"id": "ENSG00000187323", "gene_info": {"symbol": "DCC", "name": "DCC netrin 1 receptor", "geneid": "ENSG00000187323"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/15730872", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P43146"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/15730872", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/15730872", "mined_sentences": [{"text": "In particular, a recent report that DCC is regulated through the ubiquitin-proteosome system via Siah/Sina proteins, is consistent with a potential involvement in genetic and sporadic forms of Parkinson's disease.", "section": "abstract", "t_start": 36, "d_end": 211, "d_start": 193, "t_end": 38}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 8.6}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2005-01-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.086}, "type": "literature", "id": "8ac84061419215cee236d9820881d114"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/17167170"}]}, "target": {"id": "ENSG00000112033", "gene_info": {"symbol": "PPARD", "name": "peroxisome proliferator activated receptor delta", "geneid": "ENSG00000112033"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/17167170", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/Q03181"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/17167170", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/17167170", "mined_sentences": [{"text": "These results demonstrate that subtype-selective PPARdelta agonists possess antiapoptotic properties in vitro, which may underlie their potential neuroprotective potential in in vivo experimental models of cerebral ischemia and Parkinson's disease (PD).", "section": "abstract", "t_start": 49, "d_end": 246, "d_start": 228, "t_end": 57}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 8.2}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2007-03-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.08199999999999999}, "type": "literature", "id": "4a114c824eb03e02cb9736d82de4b1c3"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/11161607"}]}, "target": {"id": "ENSG00000112096", "gene_info": {"symbol": "SOD2", "name": "superoxide dismutase 2, mitochondrial", "geneid": "ENSG00000112096"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/11161607", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P04179"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/11161607", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/11161607", "mined_sentences": [{"text": "In the present study we investigated the susceptibility of mice with a partial deficiency of SOD2 to the neurotoxins 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP), 3-nitropropionic acid (3-NP), and malonate, which are commonly used animal models of Parkinson's and Huntington's disease.", "section": "abstract", "t_start": 93, "d_end": 265, "d_start": 255, "t_end": 96}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 8.2}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2001-01-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.08199999999999999}, "type": "literature", "id": "397edf3be20213135a57d922950eca73"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/21685825"}]}, "target": {"id": "ENSG00000112033", "gene_info": {"symbol": "PPARD", "name": "peroxisome proliferator activated receptor delta", "geneid": "ENSG00000112033"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/21685825", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/Q03181"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/21685825", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/21685825", "mined_sentences": [{"text": "Moreover, reports from in vivo studies using models of ischemia reperfusion and Parkinson disease also have shown neuroprotection conferred by PPAR-\u03b4.", "section": "abstract", "t_start": 143, "d_end": 96, "d_start": 80, "t_end": 148}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 8.0}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2012-01-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.08}, "type": "literature", "id": "dc4e9ba282ef12da9736b522735ba78a"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/23785434"}]}, "target": {"id": "ENSG00000112096", "gene_info": {"symbol": "SOD2", "name": "superoxide dismutase 2, mitochondrial", "geneid": "ENSG00000112096"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/23785434", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P04179"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/23785434", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/23785434", "mined_sentences": [{"text": "Polymorphisms in SOD2 have been associated with the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, as well as psychiatric disorders, such as schizophrenia, depression and bipolar disorder.", "section": "abstract", "t_start": 17, "d_end": 137, "d_start": 119, "t_end": 20}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 8.0}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2013-01-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.08}, "type": "literature", "id": "cc665e638bb2084380f9f70777e60b32"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/20800516"}]}, "target": {"id": "ENSG00000112096", "gene_info": {"symbol": "SOD2", "name": "superoxide dismutase 2, mitochondrial", "geneid": "ENSG00000112096"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/20800516", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P04179"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/20800516", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/20800516", "mined_sentences": [{"text": "Gene expression profiling of normal and SOD2 deficient erythroblasts identified the Parkinson's disease locus DJ-1 (Park7) as a differentially expressed transcript.", "section": "abstract", "t_start": 40, "d_end": 102, "d_start": 84, "t_end": 43}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 8.0}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2010-10-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.08}, "type": "literature", "id": "2d88b547443dd4036b04e07231681a10"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/22748019"}]}, "target": {"id": "ENSG00000187323", "gene_info": {"symbol": "DCC", "name": "DCC netrin 1 receptor", "geneid": "ENSG00000187323"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/22748019", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P43146"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/22748019", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/22748019", "mined_sentences": [{"text": "The expression of Pbx1 in dopaminergic neurons and its regulation of DCC expression make it an important player in defining the axonal guidance of the midbrain dopaminergic neurons, with possible implications for the normal physiology of the nigro-striatal system as well as processes related to the degeneration of neurons during the course of Parkinson's disease.", "section": "abstract", "t_start": 69, "d_end": 363, "d_start": 345, "t_end": 71}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 7.8}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2012-01-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.078}, "type": "literature", "id": "831156be72b4599b40b6dd2050844f6a"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/26887567"}]}, "target": {"id": "ENSG00000106211", "gene_info": {"symbol": "HSPB1", "name": "heat shock protein family B (small) member 1", "geneid": "ENSG00000106211"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/26887567", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P04792"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/26887567", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/26887567", "mined_sentences": [{"text": "Although none of the 3 other mutation carriers displayed Parkinsonian signs, a pathogenic relationship with Parkinson's disease remains a possibility, based on the known molecular pathology of HSPB1.", "section": "abstract", "t_start": 193, "d_end": 126, "d_start": 108, "t_end": 197}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 7.8}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2016-02-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.078}, "type": "literature", "id": "b5535e045153c53d8c582c1411e1acb9"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/23727323"}]}, "target": {"id": "ENSG00000112096", "gene_info": {"symbol": "SOD2", "name": "superoxide dismutase 2, mitochondrial", "geneid": "ENSG00000112096"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson diseases"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/23727323", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P04179"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/23727323", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/23727323", "mined_sentences": [{"text": "We review SOD2's potential involvement in the progression of neurodegenerative diseases such as stroke and Alzheimer and Parkinson diseases, as well as its potential role in \"normal\" age-related cognitive decline.", "section": "abstract", "t_start": 10, "d_end": 138, "d_start": 121, "t_end": 13}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 7.8}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2013-09-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.078}, "type": "literature", "id": "ee78c78112ef44378a659bf197a8edee"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/22498097"}]}, "target": {"id": "ENSG00000112033", "gene_info": {"symbol": "PPARD", "name": "peroxisome proliferator activated receptor delta", "geneid": "ENSG00000112033"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/22498097", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/Q03181"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/22498097", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/22498097", "mined_sentences": [{"text": "The neuroprotective effects of the PPAR\u03b3 full agonist, pioglitazone (20 mg/kg), partial PPAR\u03b3 agonist GW855266X (15 mg/kg) and PPAR-\u03b4 full agonist GW610742X (10 mg/kg) were investigated in the 6-hydroxydopamine (6-OHDA) model of Parkinson's disease when administered prior to or post 6-OHDA lesioning.", "section": "abstract", "t_start": 127, "d_end": 247, "d_start": 229, "t_end": 132}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 7.4}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2012-05-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.07400000000000001}, "type": "literature", "id": "1e13592ae2a1c417fb8731bd42ecf3cf"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/26028469"}]}, "target": {"id": "ENSG00000112033", "gene_info": {"symbol": "PPARD", "name": "peroxisome proliferator activated receptor delta", "geneid": "ENSG00000112033"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/26028469", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/Q03181"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/26028469", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/26028469", "mined_sentences": [{"text": "Activation of peroxisome proliferator-activated receptors (PPARs), namely PPAR\u03b3 and PPAR\u03b4, has been shown to provide neuroprotection in a number of neurodegenerative disorders, such as Alzheimer's and Parkinson's disease (PD).", "section": "abstract", "t_start": 84, "d_end": 219, "d_start": 201, "t_end": 88}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 7.2}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2015-08-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.07200000000000001}, "type": "literature", "id": "e93f9074686e6317cb912795a877afe0"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/23771339"}]}, "target": {"id": "ENSG00000179218", "gene_info": {"symbol": "CALR", "name": "calreticulin", "geneid": "ENSG00000179218"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/23771339", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P27797"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/23771339", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/23771339", "mined_sentences": [{"text": "This study examined expression of Ca(V)1 subtypes and the calcium-binding proteins calbindin, calmodulin and calreticulin in areas vulnerable and resistant to neurodegeneration in Parkinson's disease, in brain from neurologically normal individuals and patients with Parkinson's disease.", "section": "abstract", "t_start": 109, "d_end": 198, "d_start": 180, "t_end": 120}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 7.2}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2013-07-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.07200000000000001}, "type": "literature", "id": "edb4e4d72dcb03ee93d0dcf197d96e0c"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/10561523"}]}, "target": {"id": "ENSG00000112096", "gene_info": {"symbol": "SOD2", "name": "superoxide dismutase 2, mitochondrial", "geneid": "ENSG00000112096"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/10561523", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P04179"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/10561523", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/10561523", "mined_sentences": [{"text": "Hydroxyl radical (.OH) levels in blood, superoxide dismutase (SOD) activity in plasma (plasma-SOD) and in red blood cells (RBC) relative to Cu,Zn-SOD (SOD1) protein (RBC-SOD/SOD1), SOD1 protein in RBC (SOD1/RBC) and plasma (SOD1/plasma), and Mn-SOD protein in plasma (SOD2/plasma) were measured in patients with Parkinson's disease (PD), multiple-system atrophy (MSA) with parkinsonism, and in control subjects.", "section": "abstract", "t_start": 268, "d_end": 330, "d_start": 312, "t_end": 271}]}, "provenance_type": {"database": {"version": "2016-07-25", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 7.2}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "1999-11-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.07200000000000001}, "type": "literature", "id": "7fb8f5ad2415a6010799855464df59b3"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/22135673"}]}, "target": {"id": "ENSG00000112033", "gene_info": {"symbol": "PPARD", "name": "peroxisome proliferator activated receptor delta", "geneid": "ENSG00000112033"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/22135673", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/Q03181"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/22135673", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/22135673", "mined_sentences": [{"text": "To date, the neuroprotective benefits of PPAR\u03b4 agonists have been observed in models of stroke, multiple sclerosis, Alzheimer's disease, Parkinson's disease, radiation-induced brain injury, and spinal cord injury [12, 17\u201323].", "section": "introduction_and_background", "t_start": 41, "d_end": 155, "d_start": 137, "t_end": 45}, {"text": "PPAR\u03b4 agonists may exert therapeutic benefits in patients with Parkinson's disease (PD), a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra.", "section": "other", "t_start": 0, "d_end": 81, "d_start": 63, "t_end": 4}]}, "provenance_type": {"database": {"version": "2016-07-26", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 4.4}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2011-01-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.044000000000000004}, "type": "literature", "id": "4d7722c6ffe742a24a3b55d44dbcae7e"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/18776931"}]}, "target": {"id": "ENSG00000134644", "gene_info": {"symbol": "PUM1", "name": "pumilio RNA binding family member 1", "geneid": "ENSG00000134644"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/18776931", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/Q14671"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/18776931", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/18776931", "mined_sentences": [{"text": "For instance, angiogenesis-related proteins were mainly enriched among PUM1 targets whereas the transcripts coding for proteins linked to Parkinson's disease were solely enriched among PUM2 targets.", "section": "discussion", "t_start": 71, "d_end": 156, "d_start": 138, "t_end": 74}, {"text": "The analysis for PUM2 targets revealed only two terms with weak statistical significance: the p53 pathway (p<10\u22122), which was also weakly enriched among PUM1 targets (p<10\u22123), and several messages coding for proteins related to Parkinson's disease (p<2\u00d710\u22122) (Table 1, Table S4).", "section": "other", "t_start": 153, "d_end": 246, "d_start": 228, "t_end": 156}]}, "provenance_type": {"database": {"version": "2016-07-26", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 3.8}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2008-01-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.038}, "type": "literature", "id": "c388ce7bf2d8da7c96e03303158c7c78"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/22566955"}]}, "target": {"id": "ENSG00000106211", "gene_info": {"symbol": "HSPB1", "name": "heat shock protein family B (small) member 1", "geneid": "ENSG00000106211"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson\u2019s disease"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/22566955", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P04792"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/22566955", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/22566955", "mined_sentences": [{"text": "HSPB1 and HSPB5 are upregulated in the cortex of Parkinson\u2019s disease patients (Renkawek et al., 1994a, 1999).", "section": "other", "t_start": 0, "d_end": 67, "d_start": 49, "t_end": 4}, {"text": "Mouse data corroborated the human data, and showed similar elevations in both HSPB1 and HSPB5 using the transgenic Parkinson\u2019s model, alpha-SynA53T (Wang et al., 2008).", "section": "other", "t_start": 78, "d_end": 125, "d_start": 115, "t_end": 82}, {"text": "Using a viral vector, HSPB1 has been shown to have a positive effect in an in vitro model of Parkinson\u2019s disease by protecting against alpha-synuclein induced cell death (Zourlidou et al., 2004).", "section": "other", "t_start": 22, "d_end": 111, "d_start": 93, "t_end": 26}]}, "provenance_type": {"database": {"version": "2016-07-26", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 3.0}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2012-01-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.03}, "type": "literature", "id": "d846a86908da7ace7cc9b58aa3510086"}, {"literature": {"references": [{"lit_id": "http://europepmc.org/abstract/MED/24278676"}]}, "target": {"id": "ENSG00000106211", "gene_info": {"symbol": "HSPB1", "name": "heat shock protein family B (small) member 1", "geneid": "ENSG00000106211"}, "target_type": "protein_evidence", "activity": "up_or_down"}, "validated_against_schema_version": "1.2.3", "sourceID": "europepmc", "disease": {"efo_info": {"therapeutic_area": {"labels": ["nervous system disease"], "codes": ["EFO_0000618"]}, "path": [["EFO_0000618", "EFO_0005772", "EFO_0002508"], ["EFO_0000618", "EFO_0002508"]], "efo_id": "http://www.ebi.ac.uk/efo/EFO_0002508", "label": "Parkinson's disease"}, "name": ["Parkinson's"], "id": "EFO_0002508"}, "unique_association_fields": {"publicationIDs": "http://europepmc.org/abstract/MED/24278676", "disease_uri": "http://www.ebi.ac.uk/efo/EFO_0002508", "target": "http://identifiers.org/uniprot/P04792"}, "evidence": {"unique_experiment_reference": "http://europepmc.org/abstract/MED/24278676", "evidence_codes_info": [[{"eco_id": "literature_mining", "label": "Literature mining"}], [{"eco_id": "ECO_0000213", "label": "combinatorial evidence used in automatic assertion"}]], "literature_ref": {"lit_id": "http://europepmc.org/abstract/MED/24278676", "mined_sentences": [{"text": "Numerous studies have reported that elevated levels of constitutively expressed HspB1 and HspB5 are observed in pathological cells in which protein folding homeostasis is impaired by the accumulation of pathological proteins that are prone to aggregate, such as \u03b1-synuclein, \u03b2-amyloid peptide as well as polyQ mutants of huntingtin polypeptide that are responsive of Parkinson's, Alzheimer's and huntington, neurodegenerative diseases, respectively.", "section": "other", "t_start": 80, "d_end": 377, "d_start": 367, "t_end": 84}, {"text": "HspB1 and/or HspB5 accumulate in cortical Lewy bodies, Alzheimer disease plaques, neurofibrillary tangles, Rosenthal fibers of Alexander's-disease, Creutzfeldt-Jakob altered neurones as well as in synuclein deposit associated to Parkinson's disease or myopathy-associated inclusion body [102\u2013106].", "section": "other", "t_start": 0, "d_end": 247, "d_start": 229, "t_end": 4}]}, "provenance_type": {"database": {"version": "2016-07-26", "id": "EuropePMC"}}, "is_associated": true, "resource_score": {"type": "summed_total", "method": {"description": "Custom text-mining method for target-disease association"}, "value": 2.0}, "evidence_codes": ["literature_mining", "ECO_0000213"], "date_asserted": "2012-01-01T00:00:00Z"}, "access_level": "public", "scores": {"association_score": 0.02}, "type": "literature", "id": "99f9b9f3b49bb4c5160bd95621713723"}], "size": 27}